Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia

Children's Oncology Group

Status: Completed

Conditions: Untreated Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia; B-cell Childhood Acute Lymphoblastic Leukemia

Treatments: Other: laboratory biomarker analysis

Study type: Observational

Funder types: NETWORK; NIH

Identifiers

NCT01625143

NCI-2012-01976 (Registry Identifier)

CDR0000735342 (Other Identifier)

AALL12B7

COG-AALL12B7 (Other Identifier)

Details and patient eligibility

About

This laboratory study is looking into genes in samples from younger patients with relapsed acute lymphoblastic leukemia. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat cancer.

Full description

OBJECTIVES:

I. To identify global changes in the epigenome and various underlying histone modifications that characterize relapsed acute lymphoblastic leukemia (ALL).

II. To identify specific transcription factor-binding sites associated with histone alterations.

III. To correlate gene expression changes of differentially regulated genes at relapse with underlying chromatin modifications.

OUTLINE:

Archived bone marrow samples, collected at the time of diagnosis and relapse, are analyzed for gene expression and histone modifications by microarray, chromatin immunoprecipitation (ChIP) sequencing, and quantitative real-time polymerase chain reaction (qRT-PCR).

Enrollment: 40 estimated patients

Sex: All

Ages: Under 21 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Diagnosis of B-cell acute lymphoblastic leukemia

  • Paired diagnosis-relapse primary patient samples obtained from the Children's Oncology Group (COG) cell bank

Trial design

40 participants in 1 patient group

Observational

Description:

Archived bone marrow samples, collected at the time of diagnosis and relapse, are analyzed for gene expression and histone modifications by microarray, chromatin immunoprecipitation (ChIP) sequencing, and quantitative real-time polymerase chain reaction (qRT-PCR).

Treatment:

Other: laboratory biomarker analysis